Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
A Novel Glycosyltransferase Confers Resistance to Novobiocin in the Environment
EF 2023-24
Résumé
Soil bacteria compete with each other for the limited nutritional resources in their environment. Bacteria compete by producing toxic compounds, some of which humans have repurposed as antibiotics. As a protection strategy, bacteria have developed defence mechanisms against these antibiotics, rendering them ineffective. This phenomenon is called antimicrobial resistance (AMR). Antimicrobial-resistant pathogens have a detrimental impact on the efficacy of several clinical antibiotics, resulting in a global increase in healthcare costs and mortality. To find a solution for AMR, we must go back to its origins and study the evolution of antibiotic production and resistance in the soil. This will help predict emerging resistance in clinical settings and ultimately allow for the protection of our clinical antibiotics. My project explores the resistance profile of the natural product antibiotic, novobiocin. Although novobiocin is commonly produced by soil bacteria, its resistance in the environment is poorly understood. Recently, I identified a Bacillus thuringiensis (Bt) strain resistant to novobiocin through an unknown inactivation mechanism. Mass spectrometry analysis showed that the Bt strain modifies the structure of novobiocin by adding a glycosyl group. The alteration of novobiocin's structure prevents it from inhibiting DNA replication, allowing the bacteria to resist its activity. As we continue to characterize the enzyme responsible for this modification and establish a purification protocol, we can determine and clone the gene(s) responsible for its production. The discovery of this new resistance enzyme will aid in investigating the gain of resistance genes by clinical pathogens and will help us protect novobiocin for its efficient use in the clinic.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505816
Name
Abbas Amna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A Novel Glycosyltransferase Confers Resistance to Novobiocin in the Environment
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibiotic Modification; Antibiotics; Antimicrobial Resistance; Bacillus Thuringiensis; Glycosyltransferase; Healthcare; Mass Spectrometry; Novobiocin; Resistance Genes; Soil Microbes
Abstract
Soil bacteria compete with each other for the limited nutritional resources in their environment. Bacteria compete by producing toxic compounds, some of which humans have repurposed as antibiotics. As a protection strategy, bacteria have developed defence mechanisms against these antibiotics, rendering them ineffective. This phenomenon is called antimicrobial resistance (AMR). Antimicrobial-resistant pathogens have a detrimental impact on the efficacy of several clinical antibiotics, resulting in a global increase in healthcare costs and mortality. To find a solution for AMR, we must go back to its origins and study the evolution of antibiotic production and resistance in the soil. This will help predict emerging resistance in clinical settings and ultimately allow for the protection of our clinical antibiotics. My project explores the resistance profile of the natural product antibiotic, novobiocin. Although novobiocin is commonly produced by soil bacteria, its resistance in the environment is poorly understood. Recently, I identified a Bacillus thuringiensis (Bt) strain resistant to novobiocin through an unknown inactivation mechanism. Mass spectrometry analysis showed that the Bt strain modifies the structure of novobiocin by adding a glycosyl group. The alteration of novobiocin's structure prevents it from inhibiting DNA replication, allowing the bacteria to resist its activity. As we continue to characterize the enzyme responsible for this modification and establish a purification protocol, we can determine and clone the gene(s) responsible for its production. The discovery of this new resistance enzyme will aid in investigating the gain of resistance genes by clinical pathogens and will help us protect novobiocin for its efficient use in the clinic.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Abbas, Amna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~